Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas

In Vivo

Volumn 14, Issue 5, 2000, Pages 659-666

  Bodey, Bela ^a   Bodey Jr , Bela ^a   Siegel, Stuart E ^a   Kaiser, Hans E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cellular dedifferentiation; Colorectal carcinoma (CC); Extracellular matrix (ECM); Immunohistochemistry; Invasion; Matrix metalloproteinases (MMPs); Metastasis; Monoclonal antibodies (MoABs); Neoplastic tissue progression

Indexed keywords

ALKALINE PHOSPHATASE; ANTIGEN; COLLAGENASE 3; CYTOKINE; GELATINASE A; GELATINASE B; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PROTEINASE; STROMELYSIN; STROMELYSIN 2;

ANTIGEN DETECTION; ARTICLE; BLOOD VESSEL; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL TRANSFORMATION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME DEGRADATION; ENZYME HISTOCHEMISTRY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MALIGNANT TRANSFORMATION; METASTASIS; PERIPHERAL CIRCULATION; PROGNOSIS; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY;

EID: 0034579777     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (126)

1. Colorectal cancer. Identifying and screening high-risk patients
2. A new approach to fecal occult blood testing based on the detection of haptoglobin
3. Cancer statistics 1995
4. Perforated colorectal carcinomas
5. Cancer statistics, 1999
6. Screenning for colorectal neoplasia: Physicians' adherence to complete diagnostic evaluation
7. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease
8. Cytologic detection of colorectal cancer after administration of oral lavage solution
9. Recent hypotheses for the origin of colon cancer
10. Biomarkers of increased susceptibility to gastrointestinal cancer: New application to studies of cancer prevention in human subjects
11. Adenocarcinoma of the large intestine with perforation
12. An analysis of 284 patients with perforative carcinoma of the colon
13. Perforation complicating adenocarcinoma of colon and rectum
14. Perforative carcinoma of the colon and rectum
15. Penetrating obstructing and perforating carcinomas of the colon and rectum
16. Peritonites generalisees d'origine colique non traumatique. Reflexions a propos de soixante-deux observations
17. Obstructing/perforated carcinoma of the left colon treated by resection and the formation of a double colostomy
18. Obstructive and perforative colonic carcinoma: Patterns of failure
19. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor
20. Purification and properties of a gelatin-specific neutral protease from human skin
21. Cleavage of type VII collagen by interstitial collagenase and type IV collagenase (gelatinase) derived from human skin
22. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides
23. Cleavage of collagen type X by human synovial collagenase and neutrophil elastase
24. Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72-kDa type IV collagenase
25. Human 92- and 72-kilodalton type IV collagenases are elastases
26. Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages
27. A 92 kDa gelatinase (MMP-9) cleavage site in native type V collagen
28. Relation between substrate specificity and domain structure of 92-kDa type IV collagenase
29. Characteristics of 92 kDa type IV collagenase/gelatinase produced by granulocytic leukemia cells: Structure, expression of cDNA in E. coli and enzymatic properties
30. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B
31. Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein
32. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization
33. The collagenase gene family in humans consists of at least four members
34. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage
35. Degradation of proteoglycan aggregate by a cartilage metalloproteinase. Evidence for the involvement of stromelysin in the degradation of link protein heterogeneity in situ
36. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage
37. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility
38. Matrix metalloproteinase-3 (stromelysin-1). Identification as the cartilage acid metalloprotease and effect of pH on catalytic properties and calcium affinity
39. Interaction of human rheumatoid synovial collagenase (matrix metalloproteinase 1) and stromelysin (matrix metalloproteinase 3) with human a2-macroglobulin and chicken ovostatin. Binding kinetics and identification of matrix metalloproteinase cleavage sites
40. Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin)
41. A semicontinuous, high-performance liquid chromatography-based assay for stromelysin
42. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-1 in dermal fibroblast cultures
43. Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling
44. Timpl: Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens
45. Timpl: Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases
46. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): Hydrolysis of the gGly404-Ala405 peptide bond
47. Degradation of vitronectin by matrix metalloproteinases-1, -2, -3, -7, and -9
48. Direct activation of human neutrophil procollagenase by recombinant stromelysin
49. Biochemical characterization of human collagenase-3
50. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and 4-aminophenyl)mercuric acetate
51. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9
52. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin)
53. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
54. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme
55. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage
56. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
57. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors
58. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
59. Dual overexpression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy
60. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia
61. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples
62. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies
63. Metastasis of human colon tumor cells in vivo: Correlation with the overexpression of plasminogen activators and 72 kDa gelatinase
64. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas
65. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon
66. The expression of MMP-2 and TIMP-2 in patients with colorectal adenocarcinoma invaded to the submucosal and proper muscle layer
67. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy
68. The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer
69. Matrix-degrading metalloproteinases in tumor progression
70. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas
71. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers
72. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas
73. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers
74. Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma
75. Significance of MMP-9 and TIMP-1 production during liver metastasis in colorectal cancer
76. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases
77. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans
78. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
79. Gelatinase B (MMP-9) expression and survival in colorectal cancer patients
80. Proteolysis in colorectal cancer
81. Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia
82. Amplification of stromelysin-3 transcripts from carcinomas of the colon
83. Immunoalkaline phosphatase cytochemistry
84. Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies
85. Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry
86. The avidin-biotin reaction as an universal amplification system in immunoassays
87. Introduction to avidin-biotin technology
88. Prevention of nonspecific binding of avidin
89. The biotin-(strept)avidin system: Principles and applications in biotechnology
90. A genetic model for colorectal tumorigenesis
91. Genetic instability of cancer: Why metastatic tumor is unstable and a benign tumor is stable
92. Growth mechanisms and cancer progression
93. Localization of the gene for familial adenomatous polyposis on chromosome 5
94. Chromosomal banding patterns in human large bowel cancer
95. Localization of gene for human p53 tumour antigen to band 17p13
96. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene
97. Expression of the nuclear oncogene p53 in colon tumours
98. p53 mutations in colorectal cancer
99. Early alteration of cell-cycle regulated gene expression in colorectal neoplasia
100. WAF1, a potential mediator of p53 tumor suppression
101. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
102. p21-containing cyclin kinases exist in both active and inactive states
103. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme
104. Antibodies against p53 are associated with poor prognosis of colorectal cancer
105. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas
106. Low frequency and late occurence of p53 and DCC aberrations in colorectal tumours
107. p53 immunoreactive stain and early colorectal adenocarcinomas
108. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer
109. p53 expression in colorectal cancer: Relation to tumor type, DNA ploidy pattern and short-term survival
110. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology
111. Detection of the c-myc oncogene product in colonic polyps and carcinomas
112. Molecular genetics for clinical management of colorectal carcinoma. 17q, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential
113. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma
114. Decreased expression of DCC mRNA in gastric and colorectal cancer
115. Genetic diagnosis of colorectal cancer
116. Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells
117. Modulation of matrix metalloproteinase-7 (matrilysin) secretion in coculture of human colon carcinoma cells with fibroblasts from orthotopic and ectopic organs
118. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer
119. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis
120. Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells
121. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: A novel approach from immune/ inflammatory aspect
122. Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer
123. Clinicopathologic significance of urokinase receptor--and MMP-9-positive stromal cells in human colorectal cancer: Functional multiplicity of matrix degradation on hematogenous metastasis
124. Metastatic colorectal cancer cells induce matrix metalloproteinase release monocytes
125. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer